BeiGene
BeiGene
BeiGene is a life sciences biotechnology company.
BeiGene, founded in October, 2010 and headquartered in Beijing, is an anti-tumor drug developer. The founder is Wu Xiaobin. Listed on the HKEX on August 8, 2018, the company's major shareholders are Beigene, Ltd.. Rivals that have direct and indirect competition with BeiGene include Kintor, HitGen, Aprea Therapeutics, BridgeBio Pharma, etc.
- All
- News
- Analysis
- Research
Briefing Jun 02, 2021 10:03 AM
· Healthcare
Baiji Shenzhou: efficacy and safety advantages confirmed by global phase 3 head-on study of zebutinib
Briefing May 27, 2021 02:02 AM
· Healthcare
Alibaba Health Information publishes rather poor annual figures
In depth
Briefing May 18, 2021 07:35 AM
· Technology
Japan's Ministry of economy, industry and technology will discuss chip shortage with domestic automobile manufacturers
Briefing May 13, 2021 06:43 PM
· Healthcare
HealthTech Miaoshou Doctor (Tencent Investment) ahead of IPO
Research
Technology, Healthcare, Consumer StaplesWIA2020 | Rising Tech Stars 2020: Global & China's 100
Dec 09, 2020 09:57 AM
Dec 09, 2020 09:39 AM
Research
Consumer Staples, Industrials, FinancialsTech for Global, Globalization Footprints of the Established and the New
May 29, 2020 08:30 PM
Research
Consumer Staples, Industrials, FinancialsLow-Carbon Industry Expansion - Key Studies From Chinese Companies
May 28, 2020 12:40 PM
Briefing Apr 30, 2021 04:35 PM
· Healthcare
Baiji Shenzhou zebutinib CLL / SLL head to head phase III study reached the main end point
Briefing Mar 24, 2021 05:40 PM
· Healthcare
Cancer cell therapy company raised CNY 500 million in D round
Briefing Mar 01, 2021 11:55 AM
· Healthcare
Baiji Shenzhou PD-1 inhibitor price dropped by 80%
Briefing Feb 05, 2021 02:07 PM
· Healthcare
Novozyme plus R-CHOP Regimen for first-line treatment of mantle cell lymphoma
Healthcare
Sinopharm COVID Vaccine Receives WHO Emergency Use Certification
The Sinopharm Group’s COVID Vaccine is the sixth vaccine to receive safety, efficacy and quality verification from the World Health Organization (WHO). It is the first vaccine from a non-Western country to receive WHO certification.
May 11, 2021 03:35 AM
Briefing Feb 01, 2021 02:41 PM
· Healthcare
Bh009 new drug project independently researched and developed by Beihai biological Co., Ltd. was approved by China's clinical trials
Briefing Jan 07, 2021 04:13 PM
· Healthcare
Qiuzhen medical and tianguangshi have reached strategic cooperation to develop diagnostic kits and tumor drugs
Briefing Dec 31, 2020 10:20 AM
· Healthcare
Sinopharm new coronavirus vaccine approved
Briefing Dec 30, 2020 05:28 PM
· Healthcare
Another protein component special medical food was approved, and the total number of approved products increased to 57
Briefing Dec 28, 2020 03:13 PM
· Healthcare
Phase I project of Guangzhou Pharmaceutical production base of nuocheng Jianhua was completed
Briefing Nov 19, 2020 09:33 AM
· Healthcare
Baiji Shenzhou: midterm analysis of the global phase III clinical trial for the treatment of non-small cell lung cancer reached the main end point
Briefing Jul 14, 2020 11:02 AM
· Healthcare
Hillhouse Will Inject USD 1 billion in BeiGene's Share Sale
See more
Related Companies
EqualOcean Analysis
- Black Swans and Breakthroughs: China's Top 50 Innovative Public Firms in 2020
- China Speed: Two COVID-19 Vaccines Recognized by WHO
- After China's BNR and GTH Hit Nasdaq, Pan-Cancer Detector GRAIL Eyes IPO
- Bid for Molecular Tech in China's Early-Stage Cancer Detection Market
- More Room for the Medical Device Market to Grow in China
EqualOcean is an information service provider and investment research company that aims to become a global platform for industrial innovation. Founded in February 2014 and headquartered in Beijing, with a client network covering over 50 countries, the firm provides comprehensive professional services, including industry research, investment analysis, innovation consulting, data products, corporate branding and international strategy.